PATRICK SERRUYS, Erasmus University, Rotterdam
COMMENT: SPENCER KING, Piedmont Hospital, Atlanta
REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans
Six-months follow-up of patients receiving a new bioabsorbable drug-eluting stent are favourable, according to Patrick Serruys whose group has been investigating the stent which elutes everolimus in a group of 30 patients. During the ACC Annual Meeting in New Orleans he discussed with Peter Goodwin the potential benefits the new device can bring to coronary patients.
Christian Spaulding, Rene Descartes University
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
Primary PCI is even more effective
The ABT578-eluting ENDEAVOR stent has been compared head-to-head with sirolimus-eluting Cypher. Duke University's David Kandzari told us more.
[audio:http://www.audiomedica.com/podcasting/aha2005/David_Kandzari.mp3]Click here for
[...] Patrick Serruys. Spencer King. PATRICK SERRUYS, Erasmus University, Rotterdam COMMENT: SPENCER KING, Piedmont Hospital, Atlanta. REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans Six-months follow-up of patients … …more [...]
[...] Patrick Serruys. Spencer King. PATRICK SERRUYS, Erasmus University, Rotterdam COMMENT: SPENCER KING, Piedmont Hospital, Atlanta. REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans Six-months follow-up of patients … …more [...]